Standout Papers

Efficacy and Safety of Evolocumab in Reducing Lipi... 2005 2026 2012 2019 1.1k
  1. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events (2015)
    Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine
  2. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients (2016)
    Stephen J. Nicholls, Rishi Puri et al. JAMA
  3. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review (2005)
    Sarah Gould, Robert C. Scott Food and Chemical Toxicology
  4. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (2014)
    Frederick J. Raal, Narimon Honarpour et al. The Lancet
  5. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia (2014)
    Dirk Blom, Tomas Hala et al. New England Journal of Medicine
  6. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial (2014)
    Frederick J. Raal, Evan A. Stein et al. The Lancet
  7. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance (2014)
    Erik S.G. Stroes, David Colquhoun et al. Journal of the American College of Cardiology
  8. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia (2014)
    Jennifer G. Robinson, Bettina S. Nedergaard et al. JAMA
  9. Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia (2012)
    Frederick J. Raal, Robert C. Scott et al. Circulation
  10. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study (2012)
    Robert P. Giugliano, Nihar R. Desai et al. The Lancet
  11. Anti-PCSK9 Monotherapy for Hypercholesterolemia (2014)
    Michael J. Koren, Michael A. Bolognese et al. Journal of the American College of Cardiology
  12. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) (2014)
    Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology

Immediate Impact

5 by Nobel laureates 15 from Science/Nature 81 standout
Sub-graph 1 of 19

Citing Papers

Chemically Modified Platforms for Better RNA Therapeutics
2024 Standout
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
2022 Standout

Works of Robert C. Scott being referenced

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
2016 Standout
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
2015
and 1 more

Author Peers

Author Last Decade Papers Cites
Robert C. Scott 7633 3259 1432 1685 140 10.7k
R. John Simes 3297 1236 2294 2503 95 9.5k
Frederick J. Raal 10561 3340 3021 3499 323 13.7k
Jae Bum Kim 4082 434 1955 1917 252 20.1k
Mark D. Huffman 1742 1120 3145 889 238 7.4k
Ian Graham 6216 1928 5101 3083 200 15.9k
Thomas J. Cook 2015 701 726 1111 98 5.1k
Keaven M. Anderson 4187 1184 7366 2762 115 14.1k
Alistair S. Hall 1100 1210 3911 769 184 8.4k
Philip Hougaard 1672 668 757 2729 103 8.2k
Wai K. Leung 7141 358 1213 249 383 16.0k

All Works

Loading papers...

Rankless by CCL
2026